加强疫苗通过升高IL-10削弱BCG初免小鼠抗结核保护
研究在BCG初免小鼠中评估不同抗原(A1D4或CMFO)与佐剂(DMT或DT)组成的亚单位加强疫苗对IL-10表达及抗结核保护的影响。结果显示加强后淋巴结、脾和肺IL-10升高,DT佐剂组更明显且主要源于肺部T和Th细胞;用单克隆抗体阻断IL-10信号可增强BCG初免-CMFO/DT加强小鼠对300 CFU气溶胶M.tb感染的抵抗力,伴肺部抗原特异性及记忆CD4+ T细胞增加。
要点
- BCG初免后加强疫苗可升高小鼠淋巴结、脾和肺IL-10水平,DT佐剂组升高更明显。
- IL-10升高主要源于肺部T和Th细胞,DMT佐剂组升高较轻微。
- 阻断IL-10信号可增强BCG初免-CMFO/DT加强小鼠对300 CFU M.tb气溶胶感染的抵抗力。
核心结论
- 加强疫苗的佐剂和抗原组成影响BCG初免后IL-10表达,IL-10可能以情境依赖方式调节疫苗诱导免疫。
- IL-10有潜力作为初步评估加强疫苗性能的辅助生物标志物,但效用需进一步验证。
研究设计与样本
- 研究在BCG初免小鼠中评估含不同M.tb抗原(A1D4或CMFO)与佐剂(DMT或DT)的亚单位疫苗作为加强干预。
- 采用qRT-PCR检测IL-10 mRNA水平,FACS和ICS检测淋巴结、脾和肺中IL-10阳性细胞群。
- 进一步用单克隆抗体抑制IL-10受体信号,观察对T细胞应答及气溶胶M.tb感染保护效果的影响。
主要发现
- BCG初免小鼠加强后三周内淋巴结、脾和肺IL-10水平升高,表达水平、部位和时相存在差异。
- DMT佐剂组IL-10仅轻度升高,DT佐剂组升高更明显,主要归因于肺部T和Th细胞表达。
- 阻断IL-10信号可增强BCG初免-CMFO/DT加强小鼠对300 CFU M.tb气溶胶感染的抵抗力。
- 保护增强伴随肺部抗原特异性及记忆CD4+ T细胞增加。
临床怎么用
- 在BCG初免后使用含DT佐剂的加强疫苗时,需关注IL-10升高可能削弱对原发性M.tb感染的保护。
- IL-10可作为加强疫苗性能初步评估的辅助生物标志物,但尚需进一步验证。
局限性
- 研究为小鼠模型,结果外推至人群需谨慎。
- IL-10作为生物标志物的效用仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Around 90% of global tuberculosis (TB) new cases occur in adolescents and adults. The BCG vaccine, which is widely administered to infants, is inadequate for adult protection, underscoring the necessity for developing an effective booster vaccine for adult TB prevention. However, the effectiveness of these booster vaccines, especially against primary Mycobacterium tuberculosis (M.tb) infection, remains contentious, and their underlying mechanisms are not fully understood. Emerging evidence, including our previous findings, suggests that interleukin-10 (IL-10)-mediated immune regulation may influence T cell responses following booster immunization and potentially contribute to the limited efficacy observed in preventing primary M.tb infection, although this remains to be further clarified. METHODS: This study evaluated subunit vaccines incorporating different M.tb antigens (A1D4 or CMFO) and adjuvants (DMT or DT) as booster interventions in mice previously primed with BCG. qRT-PCR was employed to assess IL-10 mRNA levels, FACS and ICS were used to detect IL-10 positive cell populations in lymph nodes, spleen, and lungs one to three weeks following the booster administration. Additionally, the effects of inhibiting IL-10 receptor signaling using a monoclonal antibody (mAb) on T cell responses and the protective efficacy against aerosolized M.tb infection were further explored. RESULTS: The administration of the same adjuvant DMT in combination with different recombinant antigens A1D4 and CMFO, or with a different adjuvant, DT, to formulate CMFO/DT as booster vaccines in BCG-primed mice, led to an increase in IL-10 levels in the lymph nodes, spleen, and lungs within three weeks. This occurred despite variations in expression levels, expression sites, and expression timings. Specifically, only modest increases in IL-10 levels were observed in the DMT-adjuvanted groups, whereas a more pronounced elevation was detected in the DT-adjuvanted group. This increase in IL-10 was primarily attributed to its expression by T and Th cells in the lungs. Blocking IL-10 signaling using mAb enhanced the resistance of mice, which had received the BCG prime-CMFO/DT boost, against aerosol infection with 300 CFU of M.tb. This enhancement was achieved by increasing the presence of antigen-specific and memory CD4+ T cells in the lungs. CONCLUSION: The adjuvant and antigen composition of the booster vaccine influenced IL-10 expression following BCG priming. While IL-10 induction was relatively modest in the DMT-adjuvanted groups and was not associated with a marked change in protective efficacy, elevated IL-10 levels in the DT-adjuvanted group were accompanied by improved protection upon IL-10 blockade. These results indicate that IL-10 may contribute to the modulation of vaccine-induced immunity in a context-dependent manner. Thus, IL-10 has the potential to serve as an auxiliary biomarker for the preliminary assessment of booster vaccine performance, although its utility requires further validation.
引用
- Lei Q, Lin X, Yao Z, et al. Booster vaccine reduces BCG-primed mice's protection against primary Mycobacterium tuberculosis infection by raising IL-10 levels. Vaccine. 2026. PMID: 42308982. doi:10.1016/j.vaccine.2026.128841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。